|
Tipton, KS | An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12
People receiving tirzepatide-B12 products from compounders, telehealth companies, medspas, or anyone else should be aware that they may be using a potentially dangerous product with unknown risks.
https://investor.lilly.com/news-releases/news-release-details/open-l...
| |
|
tirzepatide and B12
